NASDAQ:MDGLMadrigal Pharmaceuticals Stock Price, Forecast & News

$110.32

-3.67 (-3.22 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$110.32

Now: $110.32▼

$114.14

50-Day Range

$67.09

MA: $99.93▼

$125.71

52-Week Range

$56.82

Now: $110.32▼

$127.25

Volume108,701 shs

Average Volume203,273 shs

Market Capitalization$1.70 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.3

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Madrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $163.29, Madrigal Pharmaceuticals has a potential upside of 48.0% from its current price of $110.32.
Amount of Analyst Coverage
Madrigal Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Madrigal Pharmaceuticals has received 391 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Madrigal Pharmaceuticals has received 296 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Madrigal Pharmaceuticals has received 56.91% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Madrigal Pharmaceuticals and other stocks. Vote “Outperform” if you believe MDGL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDGL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Madrigal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Madrigal Pharmaceuticals does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.89% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
71.06% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Madrigal Pharmaceuticals are expected to decrease in the coming year, from ($10.03) to ($11.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Madrigal Pharmaceuticals is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Madrigal Pharmaceuticals is -16.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Madrigal Pharmaceuticals has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.65 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:MDGL

Previous Symbol

CUSIP87162T20

CIK1157601

Webwww.madrigalpharma.com

Phone267-824-2827

Debt

Debt-to-Equity RatioN/A

Current Ratio15.93

Quick Ratio15.93

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$27.00 per share

Price / Book4.09

Profitability

EPS (Most Recent Fiscal Year)($5.45)

Net Income$-83,950,000.00

Net MarginsN/A

Return on Equity-24.72%

Return on Assets-23.60%

Miscellaneous

Employees17

Outstanding Shares15,429,000

Market Cap$1.70 billion

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

How has Madrigal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MDGL shares have increased by 36.1% and is now trading at $110.32. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Madrigal Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Madrigal Pharmaceuticals.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Madrigal Pharmaceuticals.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.34) EPS for the quarter, missing analysts' consensus estimates of ($1.94) by $0.40. View Madrigal Pharmaceuticals' earnings history.

What price target have analysts set for MDGL?

9 equities research analysts have issued 12 month price targets for Madrigal Pharmaceuticals' stock. Their forecasts range from $116.00 to $205.00. On average, they anticipate Madrigal Pharmaceuticals' share price to reach $163.29 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price. View analysts' price targets for Madrigal Pharmaceuticals.

What are Wall Street analysts saying about Madrigal Pharmaceuticals stock?

Here are some recent quotes from research analysts about Madrigal Pharmaceuticals stock:

1. According to Zacks Investment Research, "Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. " (3/4/2020)
2. HC Wainwright analysts commented, "We are confident that the MAESTRO-NASH trial is well-managed: it is conducted by PRA Health Sciences (private), a top CRO that was awarded the 2019 CRO a top drawer group of clinical site investigators including principal investigator Dr. Antonio, TX. Importantly, MAESTRO-NASH’s 52-week treatment period was selected in order to optimize patient compliance and the repeat biopsy rate, as both drop off considerably in trials that last more than one year." (7/3/2019)
3. Stifel Nicolaus analysts commented, "We believe resmetirom’s Phase 2b data are encouraging on NASH resolution and emerging evidence continues to point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. We are positively biased heading into Phase 3 however; we see few company specific catalysts to drive shares upward in the next ~12-18 months and think the stock could be volatile around updates from competitors (i.e. VKTX, GNFT, etc.) – this leads to our Hold rating. Ultimately, we feel MDGL will largely remain range bound before it reports Phase 3, 52-week data in 2H21 and based on our diligence for our NASH white paper (link here), we suspect any strategic acquirer would want to confirm resmetirom’s safety/efficacy profile and gain some commercial validation for the NASH category, as a whole, before paying a large price tag for MDGL. So a near-term takeout is unlikely, in our view." (6/24/2019)

Has Madrigal Pharmaceuticals been receiving favorable news coverage?

Headlines about MDGL stock have been trending very negative on Wednesday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Madrigal Pharmaceuticals earned a news impact score of -3.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutMadrigal Pharmaceuticals.

Are investors shorting Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 3,390,000 shares, an increase of 16.5% from the April 15th total of 2,910,000 shares. Based on an average trading volume of 201,900 shares, the short-interest ratio is presently 16.8 days. Currently, 34.3% of the company's stock are sold short. View Madrigal Pharmaceuticals' Current Options Chain.

Who are some of Madrigal Pharmaceuticals' key competitors?

Some companies that are related to Madrigal Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Viking Therapeutics (VKTX), Advaxis (ADXS), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Consolidated Water (CWCO).

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:

Dr. Paul A. Friedman, Chairman & CEO (Age 76)
Dr. Rebecca A. Taub, Founder, Exec. VP of R&D, Chief Medical Officer and Director (Age 67)
Mr. Marc R. Schneebaum, Sr. VP & CFO (Age 65)
Mr. Thomas W. Hare, Sr. VP of Clinical Management

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (5.66%), BlackRock Inc. (4.08%), State Street Corp (3.09%), Alliancebernstein L.P. (2.66%), Rock Springs Capital Management LP (1.62%) and Jennison Associates LLC (1.46%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc, Fred B Craves, Marc R Schneebaum, Paul A Friedman and Rebecca Taub. View institutional ownership trends for Madrigal Pharmaceuticals.

Which institutional investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Jennison Associates LLC, Shikiar Asset Management Inc., Deutsche Bank AG, Alps Advisors Inc., Wells Fargo & Company MN, Engineers Gate Manager LP, and Mutual of America Capital Management LLC. View insider buying and selling activity for Madrigal Pharmaceuticals.

Which institutional investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Alliancebernstein L.P., BlackRock Inc., Frontier Capital Management Co. LLC, Aviva PLC, State Street Corp, Two Sigma Investments LP, and Geode Capital Management LLC. Company insiders that have bought Madrigal Pharmaceuticals stock in the last two years include Fred B Craves, and Paul A Friedman. View insider buying and selling activity for Madrigal Pharmaceuticals.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $110.32.

How big of a company is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has a market capitalization of $1.70 billion. The biopharmaceutical company earns $-83,950,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Madrigal Pharmaceuticals employs 17 workers across the globe.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at 267-824-2827 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff